Ysios Capital hires Thomas Harth from Gimv

Harth will join Ysios as principal in Barcelona, where he will be responsible for sourcing and evaluating investment opportunities. 

He joins from Gimv, where he was senior associate within the health and care team, working out of the Antwerp office.

He co-led investments in Anjarium biosciences, where Gimv led a CHF 61m Series A round and worked on a USD 40m Series A for Kinaset Therapeutics. 

He holds a master's degree in bioengineering and applied economics, from the University of Ghent. 

He will also represent Ysios as a board member at its portfolio companies. 

Ysios closed its third fund in May 2021 at EUR 216m, it provides financing to early- and mid-stage life sciences companies that develop disruptive therapeutic products and platform technologies. 

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• People
• Southern Europe
• Ysios Capital
• Gimv